CVS Health (CVS) stock in focus as Glenview Capital trims a third of its stake after the company's Q1 2025 earnings beat.

Activist investor Glenview Capital is reducing its stake in healthcare giant CVS Health following its first-quarter earnings ...

Following healthy Q1 results and increased annual guidance, Glenview reduced its overall ... With this rebalancing, CVS Health remains our largest position, and we have no plans for additional ...

The summary highlights significant updates in the health sector, including Glenview Capital reducing its CVS stake, WeightWatchers' filing for bankruptcy, FDA's bargaining session cancellations, Novo ...

Trump's drug pricing order delivers blow to pharmacy benefit managers President Donald Trump on Monday delivered a blow to the private-sector middlemen who negotiate U.S. drug prices in his ...

It is a fictional representation created for illustrative purposes only. Glenview Capital, a prominent activist investor, has reduced its investment in CVS Health following its robust first-quarter ...

Proxy advisor opposes Holcim chairman's $58 million compensation package Proxy advisor Ethos has called on Holcim shareholders to reject the company's remuneration proposals, saying Chairman Jan ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Shareholders appeared unconcerned with CVS Health Corporation's (NYSE:CVS) lackluster earnings report last week. Our analysis suggests that while the profits are soft, the foundations of the ...